Related Experiment Videos
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential
Mariëlle I Gallegos Ruiz1, Karijn Floor, Paul Roepman
1Department of Medical Oncology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands.
Background:
Lung cancer causes approximately 1.2 million deaths per year worldwide, and non-small cell lung cancer (NSCLC) represents 85% of all lung cancers. Understanding the molecular events in non-small cell lung cancer (NSCLC) is essential to improve early diagnosis and treatment for this disease.
Methodology And Principal Findings:
In an attempt to identify novel NSCLC related genes, we performed a genome-wide screening of chromosomal copy number changes affecting gene expression using microarray based comparative genomic hybridization and gene expression arrays on 32 radically resected tumor samples from stage I and II NSCLC patients. An integrative analysis tool was applied to determine whether chromosomal copy number affects gene expression. We identified a deletion on 14q32.2-33 as a common alteration in NSCLC (44%), which significantly influenced gene expression for HSP90, residing on 14q32. This deletion was correlated with better overall survival (P = 0.008), survival was also longer in patients whose tumors had low expression levels of HSP90. We extended the analysis to three independent validation sets of NSCLC patients, and confirmed low HSP90 expression to be related with longer overall survival (P = 0.003, P = 0.07 and P = 0.04). Furthermore, in vitro treatment with an HSP90 inhibitor had potent antiproliferative activity in NSCLC cell lines.
Conclusions:
We suggest that targeting HSP90 will have clinical impact for NSCLC patients.
Insights
A common deletion in non-small cell lung cancer (NSCLC) affects HSP90 gene expression. Low HSP90 expression correlates with better survival, and HSP90 inhibitors show potent anti-cancer activity in NSCLC cells.
Area of Science:
- Genomics
- Oncology
- Molecular Biology
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer death globally, accounting for 85% of all lung cancer cases.
- Understanding the molecular underpinnings of NSCLC is critical for improving patient outcomes through early diagnosis and targeted therapies.
Purpose of the Study:
- To identify novel genes associated with NSCLC by screening for chromosomal copy number alterations affecting gene expression.
- To investigate the clinical significance of identified alterations and their impact on patient survival.
Main Methods:
- Genome-wide screening using microarray-based comparative genomic hybridization and gene expression arrays on 32 stage I and II NSCLC tumor samples.
- Integrative analysis to correlate chromosomal copy number changes with gene expression.
- Validation in three independent NSCLC patient cohorts.
Main Results:
- A deletion at 14q32.2-33 was identified in 44% of NSCLC samples, significantly impacting the expression of Heat Shock Protein 90 (HSP90).
- Low HSP90 expression was strongly correlated with improved overall survival across multiple patient cohorts (P = 0.008, P = 0.003, P = 0.07, P = 0.04).
- In vitro studies demonstrated that HSP90 inhibitors possess significant antiproliferative activity against NSCLC cell lines.
Conclusions:
- The study identifies a specific genomic alteration and its associated gene (HSP90) as a potential prognostic marker in NSCLC.
- Targeting HSP90 presents a promising therapeutic strategy with potential clinical impact for NSCLC patients.
